B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

MAPKAPK2

MOLECULAR TARGET

MAPK activated protein kinase 2

UniProt: P49137NCBI Gene: 926121 compounds

MAPKAPK2 (MAPK activated protein kinase 2) is targeted by 21 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MAPKAPK2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1tozasertib4.3375
2ponatinib4.2670
3silmitasertib3.7843
4regorafenib3.5634
5rottlerin3.2625
6lestaurtinib3.0420
7lenvatinib3.0420
8bms 7548072.309
9rebastinib2.208
10gsk 10709162.208
11encorafenib2.208
12amg 9002.087
13cep 324961.956
14bafetinib1.956
15tanzisertib1.956
16talmapimod1.956
17osi 6321.795
18fgfr inhibitor debio 13471.795
19losmapimod1.795
20Adenosine Triphosphate1.102
21Afatinib0.691

About MAPKAPK2 as a Drug Target

MAPKAPK2 (MAPK activated protein kinase 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 21 compounds with documented MAPKAPK2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MAPKAPK2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.